Memantine reduces opioid use but not pain in knee osteoarthritis patients after surgery
This Common Memory Drug Cuts Opioid Use After Knee Replacement
A randomized controlled trial in adults with knee osteoarthritis found memantine did not significantly lower pain scores versus placebo, but…
A drug already approved for Alzheimer's disease may help knee replacement patients rely less on opioids during recovery — even if it does no…
Pitavastatin showed no difference in health-related quality of life compared with placebo in people with HIV.
Why Heart Risk Factors Drag Down Daily Wellbeing for People With HIV
This randomized controlled trial evaluated pitavastatin versus placebo in 733 people with HIV aged 40 to 75 years on antiretroviral therapy …
Common heart risks like smoking and high BMI hurt daily physical wellbeing for people with HIV, while statins showed no visible improvement …
Nerinetide showed no significant association with brain volume changes in stroke patients receiving endovascular therapy.
A Hidden Brain Injury Keeps Growing After a Stroke
This prospective, multisite MRI sub-study of the ESCAPE-NA1 trial included 43 patients receiving endovascular therapy (EVT) for stroke. The …
A stroke's damage keeps unfolding for three months as hidden brain shrinkage spreads, offering a roadmap for new protective drugs during the…
Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disorders.
Why Galantamine Failed to Help
In a double-blind, randomized, placebo-controlled crossover study, people with HIV on antiretroviral therapy received galantamine or placebo…
Galantamine, a drug used for memory loss, did not improve brain fog in people with HIV, even though it increased a key inflammation marker.
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history.
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease.
A New Alzheimer's Drug Shows Stronger Promise for Most People at Risk
This Phase 3 subgroup analysis of an RCT evaluated lecanemab in 1,521 individuals with early Alzheimer's disease who were ApoE4 non-carriers…
For the majority of people facing early Alzheimer's, starting this treatment sooner may help preserve more of their daily life for longer.
Phase 2 trial finds mezagitamab increases platelet counts in adults with persistent or chronic ITP
Mezagitamab increased platelet counts in adults with chronic or persistent immune thrombocytopenia in this early trial.
A multicenter, double-blind, randomized, placebo-controlled Phase 2 trial in 41 adults with persistent or chronic ITP found 91% of participa…
Mezagitamab helped 91% of adults with chronic low platelet counts reach target levels, while only 23% on placebo did so in this early trial.
N-acetylcysteine protocol study for early-onset preeclampsia progression in Lagos, Nigeria
NAC study protocol for early-onset preeclampsia in Lagos hospitals planned for 2026 to 2028
This study protocol outlines a planned proof-of-concept trial evaluating daily oral N-acetylcysteine versus placebo in sexually active women…
A planned 2026 trial in Lagos hospitals will test if a daily antioxidant tablet slows the progression of early-onset preeclampsia in pregnan…
Hydroxychloroquine did not prevent SLE progression in incomplete lupus patients in randomized trial
Hydroxychloroquine did not slow disease progression in incomplete lupus patients over two years
A randomized, double-blind trial of 180 patients with incomplete lupus erythematosus found hydroxychloroquine did not reduce progression to …
Hydroxychloroquine failed to slow lupus progression in patients with early symptoms over two years, matching placebo results.